Healthcare Industry News: bivalirudin
News Release - March 15, 2007
The Medicines Company Products Angiomax(R) (bivalirudin) and Cleviprex(TM) (clevidipine) Featured in Three Late Breaking Trials at American College of Cardiology Annual Scientific SessionAngiomax ACUITY trial one-year data on March 26
Cleviprex Phase III ECLIPSE findings on March 26 and 27
PARSIPPANY, N.J.--(HSMN NewsFeed)--The Medicines Company (NASDAQ: MDCO ) today announced that three presentations of late breaking trial results featuring Angiomax® (bivalirudin) and Cleviprex(TM) (clevidipine) have been scheduled for the American College of Cardiology (ACC) Annual Scientific Session March 24-27, 2007 in New Orleans.
"We are proud that scientific innovation at The Medicines Company is recognized with a wealth of data presentations at one of the world's leading medical meetings," said John Kelley, President and Chief Operating Officer at The Medicines Company. "We are particularly excited to have both Angiomax and Cleviprex trials featured, demonstrating the strength of our acute care hospital franchise."
On Monday, March 26th from 2:00- 2:15 PM, a late breaking presentation is scheduled as, "A Prospective, Randomized Trial of bivalirudin in Acute Coronary Syndromes: Final One-Year Results from the ACUITY Trial." The primary 30-day results of ACUITY were presented at ACC last year and were published in The New England Journal of Medicine on November 23, 2006.
On Monday, March 26, from 4:15-4.30 PM, a late breaking presentation is scheduled as, "Blood Pressure Control Is an Independent Predictor of Short-term Mortality in Cardiac Surgery Patients: Analysis From the Three Randomized ECLIPSE Trials."
On Tuesday, March 27, from 12:00-12:15 PM, a late breaking presentation is scheduled as, "Blood Pressure Control With Clevidipine Compared With Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Perioperative Hypertension: Results of the Three Randomized ECLIPSE Trials."
In addition, eight data abstract presentations were accepted with results from the ACUITY trial of Angiomax. These include analyses of moderate and high risk patients with Acute Coronary Syndromes (ACS) and:
- Renal insufficiency
- Major bleeding events
- Patients admitted through the emergency department
- Major bleeding and pro-inflammatory response
- Hemoglobin decrease in the absence of overt bleeding after PCI
- Chronic kidney disease
- The impact of clopidogrel treatment and timing prior to Coronary Artery Bypass Graft Surgery
- Patients undergoing Bypass Graft Surgery
The dial in information is listed below:
Domestic Dial In: 800-810-0924
International Dial In: 913-981-4900
Replay is available from 9:00 p.m. Eastern Time following the conference call through Monday, April 16th. To hear a replay of the call dial 888-203-1112 (domestic) and 719-457-0820 (international). Passcode for both dial in numbers is 3194796.
About The Medicines Company: The Medicines Company is committed to delivering innovative, cost-effective acute care hospital products in the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Company also has two products in late-stage development, Cleviprex(TM) (clevidipine) and cangrelor. The Company's website is http://www.themedicinescompany.com.
Statements contained in this press release about The Medicines Company that are not purely historical, and all other statements that are not purely historical, may be deemed to be forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, the words "believes," "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. Important factors that may cause or contribute to such differences include whether we are successful in extending the term of the patent, the extent of the commercial success of Angiomax, whether the Company's products will advance in the clinical trials process, whether the Company's product candidates will receive approvals from regulatory agencies, and such other factors as are set forth in the risk factors detailed from time to time in the Company's periodic reports and registration statements filed with the Securities and Exchange Commission including, without limitation, the risk factors detailed in the Company's annual report filed on March 1, 2007, which are incorporated herein by reference. The Company specifically disclaims any obligation to update these forward-looking statements.
Source: The Medicines Company
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.